Los puntos clave no están disponibles para este artículo en este momento.
The addition of bevacizumab to neoadjuvant chemotherapy significantly increased the rate of pathological complete response, which was the primary end point of this study. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00408408.).
Bear et al. (Thu,) studied this question.